Introduction {#Sec1}
============

Pathogenic variants in *PCDH19* are associated with early onset, clustered epileptic seizures often provoked by fever, intellectual disability (ID) that can be present in variable degrees and behavioural disturbances such as autistic features, attention deficit, hyperactivity and aggression. The clinical features may resemble those of Dravet syndrome (phenotype MIM \# 300088) \[[@CR1]--[@CR5]\].

*PCDH19* is located at Xq22.1 and codes for protocadherin-19, a transmembrane protein involved in neuronal organization and migration and cell-cell and cell-matrix adhesion \[[@CR6]--[@CR10]\]. It is highly expressed in the central nervous system \[[@CR1]\]. *PCDH19*-related epilepsy shows a remarkable inheritance pattern: generally, females carrying heterozygous pathogenic variants are affected, whereas hemizygous male carriers are asymptomatic or only show psychiatric or behavioural symptoms \[[@CR1], [@CR2], [@CR11], [@CR12]\]. However, in 2009, the first affected male mosaic for a *PCDH19* pathogenic variant was described \[[@CR2]\]. This finding gave rise to a theory of cellular interference as disease mechanism: disease occurs when two different cell populations exist (cells expressing the normal *PCDH19* protein and cells expressing a mutant form of the protein), as is true for heterozygous and mosaic pathogenic variants, but not for hemizygous pathogenic variants in males. These non-homogeneous cell populations are likely to disrupt cell-cell interactions, leading to disease \[[@CR2]\].

Only four affected mosaic male patients have been described in literature until now, the oldest being 7 years old \[[@CR2], [@CR13], [@CR14]\]. Here, we report five additional male patients with mosaic *PCDH19* mutations, of ages 2, 10, 13, 13 and 14 years old. We compared the male and female phenotypes.

Methods {#Sec2}
=======

Patients and molecular analysis {#Sec3}
-------------------------------

All five patients were selected for diagnostic genetic testing because of developmental delay and/or epilepsy. Genetic testing on DNA from lymphocytes was performed using a custom targeted next generation sequencing (NGS) gene panel for epilepsy genes (see online resource [1](#MOESM1){ref-type="media"} for details). Mosaicism of *PCDH19* variants was determined based on the simultaneous presence of a variant allele and the reference allele, as *PCDH19* is located on the X-chromosome and all patients were male. The percentage of mosaicism was based on the percentage of reads that showed the alternate allele. *PCDH19* mosaic male patients from different centres were collected through personal communication between authors, meaning no structured cohort was tested. Detailed clinical data were collected from medical records. The parents of all patients gave informed consent for the publication of clinical data.

Literature search {#Sec4}
-----------------

A literature study was carried out in the PubMed database to identify previously described patients with *PCDH19* pathogenic variants.

Results {#Sec5}
=======

Molecular analysis {#Sec6}
------------------

All five patients carried a *PCDH19* variant in various degrees of mosaicism (patient A: c.1864G \> C, p.Gly622Arg, 60%; patient B: c.840C \> G, p.Tyr280\*, 22%; patient C: c.462C \> G, p.Tyr154\*, 65%; patient D: c.1682C \> G, p.Pro561Arg, 78%; patient E: c.799G \> T p.Glu267\*, 20%, RefSeq NM_001184880). According to American College of Medical Genetics and Genomics (ACMG) criteria, the variant of patient A was classified as likely pathogenic, and the variants of patient B-D were classified as pathogenic. The variants of patient B, C and E lead to a premature stopcodon; the variants of patient A and D were both predicted probably damaging and damaging by PolyPhen and SIFT, respectively. None of the variants was present in control databases (Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP) and the the Exome Aggregation Consortium (ExAC) database). The Pro561Arg variant has been previously described in two affected female siblings with ID, microcephaly and seizures and was paternally transmitted \[[@CR15]\]; the other variants are novel. All variants were confirmed de novo, except for the variant in patient D, whose parents were not tested. No other variants that could explain the phenotypes were found.

Clinical characteristics of the newly reported and previously described male patients with de novo *PCDH19* pathogenic variants are summarized and compared to those of previously published females in Table [1](#Tab1){ref-type="table"}. See online resource for extensive clinical descriptions (online resource 2). Overall, all patients had normal development before seizure onset, occurring between 5 and 10 months of age, except for patient E. This patient had a delay in speech development, like his father, before onset of seizures and seizure onset occurred later, at 31 months. First seizure types were generalized clonic or clusters of focal or complex partial seizures. Later seizures were mainly complex partial seizures and primary or secondary generalized clonic and tonic-clonic seizures. In all five patients, seizures tended to cluster and could be provoked by fever. Four out of five patients had mild to severe ID, autism and additional behavioural problems.Table 1Clinical description of male and female patients carrying *PCDH19* likely pathogenic variantsPatientABCDEF \[[@CR2]\]G \[[@CR13]\]H \[[@CR14]\]I \[[@CR14]\]Female patients^d^Age at inclusion (years)10131424 months137643,51--54Variant^a^c.1864G \> C, p.Gly622Argc.840C \> G, p.Tyr280\*c.462C \> G, p.Tyr154\*c.1682C \> G,\
p.Pro561Argc.799G \> T, p.Glu267\*del *PCDH19*c.605C \> A, p.Ser202\*c.918C \> G, p.Tyr306\*c.1352 C \> T, p.Pro451Leu*PCHD19* deletions, duplications, missense and nonsense variants% of mosaicism60% (blood)22% (blood)65% (blood)78% (blood)20% (blood)100% (lymphocytes), 47% (fibroblasts)50% (blood), 70% (buccal cells), 100% (urine sediment)10% (lymphocytes, saliva, hair)90% (lymphocytes, urine)−Technique used (number of alternate alleles/total read depth at base position)NGS gene panel (92/153 reads)NGS gene panel (77/380 reads)NGS gene panel (38/59 reads)NGS gene panel (351/450 reads)NGS gene panel (19/93 reads)Detection by microarray, estimation of % mosaicism by FISH (100 cells)Detection by exome sequencing, estimation of % mosaicism by SangerNGS gene panel (157 reads)NGS gene panel (135 reads)VariousSexMaleMaleMaleMaleMaleMaleMaleMaleMaleFemaleExam at birthMeconium stained amniotic fluid, bradycardiaNormalNormalUmbilical cord around neck, quick recoveryNormal?Normal??NormalDevelopment prior to sz onsetNormalNormalNormalNormalSpeech delayNormalNormalNormalNormalNormalSz onset age (months)510107311299103--70 (most \<12)Sz type at onsetGeneralized, clonic (fs)Generalized clonicCluster of CP seizuresClusters of focal sz, generalizing to GTC and tonic seizuresClusters of focal sz, generalizing to one hemisphereGTC (fs, prolonged, repetitive)Focal myoclonic, tonic--clonic, FSsGAfebrile hypotonic seizure with hypopnea (40 min)24 h cluster of febrile sz with fixed gaze, loss of contact, upper limb hypertonia,\
and jerks (30--40 s.)Febrile, febrile SE, afebrile; GTC, generalized tonic; hemiconvulsion; focal, FSsG; CPLater sz typesCP, secondary generalized. Focal with affective symptoms, secondary generalized. Primairy generalizedGeneralized clonicCP, secondary tonic clonic, tonic,\
statusFocal, febrile, GTC, tonic, CPCP, febrileHemiclonic, GTC, myoclonic jerksFocal myoclonic, tonic--clonic, rapid secondary generalizationFS, focal tonic-vibratoryFS and afebrile seizure clusters, tonic. Often fearful screaming at startFS or afebrile; generalized clonic, tonic, tonic-clonic or atonic; hemiclonic; focal, CP, FSsG, myoclonic; absences; SEClusters of sz+ (fever related)+++++?+++Focal sz with affective symptoms+−+−+???++Fever sensitivity++++++?+++AEDs used and response^b^VPA: -, LTG: -, CBZ:-VPA: +VPA:?, LEV: +/−, LZP (during clusters): -, TPM, CBZ, OXC, PHT, PHB, LTG, CLB, VGB:?LEV:+/−, TPM: -, OXC:-, VPA:+, PHB:+, LSM:-, Diazepam:-VPA:+; CBZ: +/−; OXC: +/−VPA, CLB, CLN, TPM, STP:?LEV: +/−, ZNS: +, multiple AEDs: -VPA:?PHB:?, VPA:LEV, VPA, CLB, CLN, TPM, STP, LTG, PHB, CBZ, OXC, ZNS, NTZ, VGB, KBR, LZP: different responsesCurrent AEDs^b^LEV, OXC, CLB, TPMVPALEVOXC, VPA, PHB, LEVOXC?ZNS−PHB, VPAMany different AED's, some cases no AED'sSz outcome1 cluster of sz per year (5--10 sz/cluster)Last sz at age 10 yearsOngoing szOngoing szOngoing sz during febrile illnessPersistence of febrile sz in spite of treatmentSeizure free for 20 monthsSeizure free age 14--42 months (no AEDs), since then 1 cluster of sz4--5 clusters per yearOften seizures less frequent or seizure free at certain age (4--36 years)EEG at onset7--8 months: normal. 10--11 months: asymmetrical background activity, non-specific high voltage delta-activity occipital right \> left.Frequent generalized epileptic discharges2 years: normalMultiple focal discharges, right centroparietal, secondary generalization. Mild diffuse background slowingFocal epileptic discharges left parietotemporal with generalization to one hemisphere (ictal)?Slower rhythm for age, mild diffuse disturbance. Infrequent right frontal, and rare\
left temporal sharp wave discharges, suggestive of epileptiform activityRare right frontotemporal sharp wavesNormalMostly normalEEG at follow-up3,5 years: normal−3 years: No epileptic activity, generalized and focal slow activity-???Bilateral centroparietal onset of seizuresNormal, interictal spikes, generalized poly-spike waves, slow waves, slow backgroundLast EEG6 years: normal background activity, diffuse fast activity mainly frontal. No epileptic activity.−4 years: No epileptic activity, generalized and focal slow activity-32 months: interictal EEG normal???Normal interictal−ID^c^++ (estimated: slowed PMD, special education)+ (IQ 66 at 5 years)++ to +++- (only delayed speech development, but no true ID yet, based on clinical evaluation)+ (IQ 55 at 9 years)++ to ++++/− (IQ = 76)+/− (GDQ 78 at 46 months, 72 at 52 months)- (GDQ 101 at 30 months and 103 at 40 months)- to +++Developmental stagnation/regression−−−−−??−−Regression in some casesLanguage (words/sentences)Delayed: words, sentencesNot delayed. First words at 12 months. Two-word sentences at 16 monthsSentences, stereotyped phrasesMildly delayed speech developmentMildly delayed speech developmentdelay: words-sentences???Sometimes normal, often delayed, words-sentences, in rare cases absentBehavioural/psychiatric disturbancesAutism, aggression, behavioural problems, ADHDAutism, mood disorderAutism spectrum disorder,\
anxiety−Behaviour problems resembling autism spectrum disorder, short attention spanBehavioural problems, autistic featuresIrritability, aggression, rigidity, poor sleep, ADHD, anxiety, OCD, ODDCompulsive and stereotyped behaviours−Prominent behavioural problems in most cases (autism, attention deficit, hyperactivity, aggression, emotional\
lability, impulsiveness, anxiety, jealousy, obsession, depression psychogenic\
nonepileptic sz)Neurological examinationCrouched gaitHypotoniaMotor delay and balance problemsBalance problems (medication induced), improvingReduced coordinationMotor delay, ataxia???Mostly normal; hypotonia, dyspraxia, ataxia or motor delay in someMRI images (age)Expanded perivascular spaces (8 years)Normal (7 years)Widened peripheral subarachnoid spacesNormal (7 months)Normal (2,5 years)?Normal? (CT: normal)Normal (10 months)Usually normal (mild atrophy/cortical dysplasia is rarely reported)Additional comments−Pes plano valgus, obesity (BMI 23.3; +2.3 SD)−Hand food mouth diseasedysmorphic features: plagiocephaly occipital/parietal area, cupped ears, intradigital webbing of phalanges. Severe myopia*SZ* seizure(s), *AED* anti-epileptic drug, *PMD* psychomotor development, *GTC* generalized tonic-clonic, *CP* partial complex, *FS* fever sensitive, *SE* status epilepticus, *FSsG* focal seizure with secondary generalization, *CBZ* carbamazepine, *CLB* clobazam, *CLN* clonazepam, *KBR* potassium bromide, *LEV* levetiracetam, *LSM* lacosamide, *LTG* lamotrigine, *LZP* Lorazepam, *NTZ* nitrazepam, *OXC* oxcarbazepine, *PHB* phenobarbital, *PHT* phentytoin, *STP* stiripentol, *TPM* topiramate, *VGB* vigabatrin, *VPA* valproic acid, *ZNS* zonisamide, *GDQ* Griffiths Developmental Quotient^a^RefSeq NM_001184880^b^"−" not effective, "+/−" slight effect, "+" good effect^c^"-" absent, "+/−" borderline, "+" mild, "++" moderate, "+++" severe^d^\[[@CR2]--[@CR5], [@CR11], [@CR12], [@CR15]--[@CR29]\]

Discussion {#Sec7}
==========

We here report five male patients with mosaic *PCDH19* likely pathogenic variants, which raises the total number of described male patients to nine \[[@CR2], [@CR13], [@CR14]\]. Four of the currently described male patients are the oldest reported so far (ages 10, 13 twice and 14 years old), which gives the opportunity to investigate whether *PCDH19*-related phenotypes evolve the same way in male and female patients. Our current findings confirm previously reported observations of similar clinical features in male and female patients, also for older children \[[@CR2], [@CR13], [@CR14]\]. Focal seizures with affective symptoms (fearful screaming) are very common in female patients and become more prevalent with an increasing age \[[@CR26]\]. This distinctive seizure type is also reported in three male patients \[14, current study\]. These similarities suggest that there are no differences in clinical consequences between phenotypes caused by postzygotic *PCDH19* pathogenic variants in mosaic males, and phenotypes caused by heterozygous *PCDH19* pathogenic variants in females. This lends further support to the hypothesis that cellular interference is the main disease mechanism, as proposed by Depienne et al. \[[@CR2]\] The increasing number of affected mosaic male patients undermines the theory of a compensating effect by the nonparalogous *PCDH11Y* gene in male patients, as proposed by Dibbens et al. \[[@CR1]\]. It is highly unlikely that this gene would only compensate for a complete absence of *PCDH19* in hemizygous affected males, but not for a partial loss of *PCDH19* in mosaic males.

In female patients, seizure frequency often diminishes around puberty \[[@CR3], [@CR5], [@CR11], [@CR28]--[@CR30]\], possibly due to hormonal changes \[[@CR30]\]. Our 13-year old patient has been seizure free since the age of 10 years old; our 10-year-old patient only has one cluster of seizures per year. However, our other 13- and 14-year-old patients still have ongoing seizures. Although four of our male patients are the oldest reported until now, none of them has reached adolescence yet, and the numbers are still small, making it hard to draw definite conclusions. Nevertheless, since some of the few reported male patients already show a reduction in seizure frequency with increasing age, it seems unlikely that a declining seizure frequency is exclusively occurring in females and is related to female specific hormones.

We hypothesised that males with a mutated allele percentage around 50% in the brain, who would have an inherent high level of cellular interference, may show a more severe clinical picture than males with a lower or higher percentage of mosaicism. High or low percentages of mosaicism would resemble skewed X-inactivation in female patients, which has also been suggested to lead to a milder phenotype \[[@CR5], [@CR15]\], although no clear correlation has been shown \[[@CR25], [@CR29]\]. Indeed, in our cohort, the three patients with the lowest and highest percentages of mosaicism in blood are the least severely affected (patients B, D and E), and two previously described patients, one with borderline ID and one with normal intelligence showed percentages of mosaicism of 10 and 90%, respectively (patients H and I). However, patient G shows an equal number of mutated and wild-type alleles in blood and is also mildly affected, and patient F shows no mosaicism in blood cells at all, only in fibroblasts, but has moderate to severe ID and ongoing seizures. It is thus not possible to predict the phenotype based on the percentage of mosaicism in blood, most likely because it does not necessarily equal the percentage of mosaicism in the brain.

The number of identified male patients mosaic for *PCDH19* pathogenic variants increases \[[@CR2], [@CR13], [@CR14]\], probably due to our improving abilities to detect mosaicism in general by using NGS techniques. It is now clear that *PCDH19* pathogenic variants can cause epilepsy both in males and females and that mosaicism for *PCDH19* pathogenic variants in males might be more common than previously thought. Because our five described patients were gathered through personal communication between authors from different diagnostic centres, no structured cohort with clearly defined inclusion criteria was tested, which makes it difficult to estimate the frequency of mosaic pathogenic *PCDH19* variants in male patients. Since the *PCDH19* and Dravet syndrome phenotypes show many similarities, testing a cohort of *SCN1A*-negative, male Dravet syndrome patients for mosaic *PCDH19* pathogenic variants could give more insight in the true incidence. In this cohort and in males with clinical features characteristic of a *PCDH19*-related disorder, NGS techniques with high coverage should be used to look for *PCDH19* pathogenic variants, as traditional Sanger Sequencing is not sensitive enough to reliably detect mosaicism. This overview helps create more knowledge about the disease course in male patients, which is extremely relevant for counselling those affected and their families. Reporting on more (older) patients in the future is essential for establishing a good understanding of prognosis in male patients.
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